Medications for Severe OCD and Anxiety

First-Line Pharmacological Treatments

The American Psychiatric Association recommends Selective Serotonin Reuptake Inhibitors (SSRIs) at higher doses than those used for depression as the first-line pharmacological treatment for severe Obsessive-Compulsive Disorder (OCD) and anxiety due to their established efficacy, tolerability, safety profile, and absence of abuse potential 1, 2, 3
Higher doses of SSRIs are typically required for OCD compared to those used for anxiety disorders or depression, with treatment maintained at the maximum recommended or tolerated dose for at least 8 weeks to determine efficacy 2, 3
When choosing an SSRI, consider adverse effect profiles, potential drug interactions, presence of comorbid conditions, past treatment response, and cost and availability 1, 2, 3, 4

OCD treatment guidelines recommend 8-12 weeks as the optimal duration to determine SSRI efficacy, with significant improvement observed within the first 2-4 weeks of treatment 3
Maintenance treatment should continue for a minimum of 12-24 months after achieving remission, with longer treatment necessary due to high risk of relapse after discontinuation 3, 5

Approximately 50% of patients with OCD fail to fully respond to first-line treatments, with augmentation strategies including adding cognitive-behavioral therapy (CBT) with exposure and response prevention (ERP) 1, 3
Other augmentation strategies include switching to a different SSRI, trying higher doses of an SSRI, or considering a serotonin-norepinephrine reuptake inhibitor (SNRI) like venlafaxine 3, 4
Pharmacological augmentation options include adding antipsychotics to SSRIs, considering clomipramine augmentation, or trying glutamatergic agents such as N-acetylcysteine or memantine 3, 4, 6

Higher doses of SSRIs are associated with greater efficacy but also higher rates of dropout due to adverse effects, requiring careful monitoring of SSRI adverse effects when establishing the optimal dose 2, 3
Antipsychotic augmentation requires careful monitoring of risk-benefit ratio, particularly for weight gain and metabolic effects, while clomipramine concerns include potentially life-threatening events such as seizures, heart arrhythmia, and serotonergic syndrome 4

The American Psychiatric Association recommends starting with either SSRIs or cognitive-behavioral therapy (CBT) with exposure and response prevention (ERP) as monotherapy, with SSRIs preferred when CBT expertise is unavailable or when severe comorbid depression is present 7, 8
SSRIs are the first-line pharmacological treatment based on efficacy, tolerability, safety, and absence of abuse potential 7, 8
CBT has larger effect sizes than pharmacotherapy (number needed to treat: 3 for CBT vs 5 for SSRIs) 8

Allow 8-12 weeks at maximum tolerated dose before declaring treatment failure, though significant improvement may be observed within 2-4 weeks 7
Continue treatment for a minimum of 12-24 months after achieving remission due to high relapse risk after discontinuation 7

Patient adherence to between-session homework (ERP exercises at home) is the strongest predictor of good outcome 8
Integrate cognitive reappraisal with ERP to make treatment less aversive and enhance effectiveness, particularly for patients with poor insight 8
Choose CBT as initial treatment when patient preference for psychotherapy, access to trained CBT clinicians is available, and absence of comorbid conditions requiring pharmacotherapy 8
Consider clomipramine as an augmentation option, which is more efficacious than SSRIs in meta-analyses, but has lower tolerability 7
Antipsychotic augmentation (risperidone, aripiprazole, quetiapine) is an evidence-based strategy for treatment-resistant patients 7

Intensive CBT protocols (multiple sessions over days, sometimes inpatient) may be used for severe or treatment-resistant patients 7, 8